Scientific Article - Review
previous document  unige:132571  next document
add to browser collection

ILC2s: new actors in tumor immunity

Vanoni, Giulia
Published in Frontiers in Immunology. 2019, vol. 10, p. 2801
Abstract Innate lymphoid cells (ILCs) represent the most recently identified family of innate lymphocytes that act as first responders, maintaining tissue homeostasis and protecting epithelial barriers. In the last few years, group 2 ILCs (ILC2s) have emerged as key regulators in several immunological processes such as asthma and allergy. Whilst ILC2s are currently being evaluated as novel targets for immunotherapy in these diseases, their involvement in tumor immunity has only recently begun to be deciphered. Here, we provide a comprehensive overview of the pleiotropic roles of ILC2s in different tumor settings. Furthermore, we discuss how different therapeutic approaches targeting ILC2s could improve the efficacy of current tumor immunotherapies.
PMID: 31849977
Full text
Article (Published version) (1.3 MB) - public document Free access
Research group Ciblage des lymphocytes sécrétant des cytokines (1015)
Project FNS: PZ00P3_161459; PR00P3_179727
(ISO format)
ERCOLANO, Giuseppe et al. ILC2s: new actors in tumor immunity. In: Frontiers in Immunology, 2019, vol. 10, p. 2801. doi: 10.3389/fimmu.2019.02801

67 hits



Deposited on : 2020-03-19

Export document
Format :
Citation style :